| Message: | PCSK9 binds the LDL (low-density lipoprotein) receptor on the surface of liver cells. The LDL receptor (LDLR) binds and initiates ingestion of LDL-particles from extracellular fluid into cells, thus reducing LDL particle concentrations. When bound to PSCK9, the LDL receptor is degraded and is no longer recycled back to the cell membrane surface to bind and ingest more LDL-particles after the LDL-LDLR particle combination has been ingested, thus resulting in reduced removal of LDL cholesterol from the blood. By blocking PCSK9, more LDLRs are recycled and are present on the surface of cells to clear LDL cholesterol from the extracellular fluid such as blood, resulting in reducing LDL cholesterol levels. Similar to many other proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pcsk9-immune-checkpoint-knock-in-mice.htm. |
my account
